Viridian Therapeutics Inc’s filing revealed that its Chief Legal Officer Tousignant Jennifer unloaded Company’s shares for reported $70796.0 on Dec 31 ’25. In the deal valued at $31.16 per share,2,272 shares were sold. As a result of this transaction, Tousignant Jennifer now holds 0 shares worth roughly $0.0.
Then, Tousignant Jennifer bought 2,272 shares, generating $70,796 in total proceeds.
Before that, Fairmount Funds Management LLC bought 454,545 shares. Viridian Therapeutics Inc shares valued at $9,999,990 were divested by the Director at a price of $22.00 per share. As a result of the transaction, Fairmount Funds Management LLC now holds 3,914,458 shares, worth roughly $124.28 million.
Wedbush reiterated its Viridian Therapeutics Inc [VRDN] rating to an Outperform in a research note published on December 10, 2025; the price target was $47. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. Truist began covering VRDN with “Buy” recommendation on November 24, 2025.
Price Performance Review of VRDN
On Monday, Viridian Therapeutics Inc [NASDAQ:VRDN] saw its stock jump 4.68% to $31.75. Over the last five days, the stock has gained 3.49%. Viridian Therapeutics Inc shares have risen nearly 51.84% since the year began. Nevertheless, the stocks have risen 2.02% over the past one year.
How much short interest is there in Viridian Therapeutics Inc?
A steep rise in short interest was recorded in Viridian Therapeutics Inc stocks on 2025-12-15, dropping by -0.43 million shares to a total of 9.04 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 9.47 million shares. There was a decline of -4.78%, which implies that there is a negative sentiment for the stock.
